WindMIL Therapeutics

OverviewSuggest Edit

WindMIL Therapeutics is a company focusing on oncology cell therapy. It develops a class of cell therapies called MILs (marrow infiltrating lymphocytes) derived from memory T cells found in the bone marrow.
TypePrivate
Founded2016
HQBaltimore, MD, US
Websitewindmiltx.com

Latest Updates

Employees (est.) (Mar 2021)25(-3%)
Cybersecurity ratingBMore

WindMIL Therapeutics Office Locations

WindMIL Therapeutics has offices in Baltimore and Philadelphia
Baltimore, MD, US (HQ)
1812 Ashland Ave #100
Philadelphia, PA, US
3675 Market St #200
Show all (2)

WindMIL Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2016

WindMIL Therapeutics total Funding

$42.5 m

WindMIL Therapeutics latest funding size

$32.50 m

Time since last funding

3 years ago

WindMIL Therapeutics investors

WindMIL Therapeutics's latest funding round in June 2018 was reported to be $32.5 m. In total, WindMIL Therapeutics has raised $42.5 m
Show all financial metrics

WindMIL Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

WindMIL Therapeutics Online and Social Media Presence

Embed Graph

WindMIL Therapeutics News and Updates

WindMIL Therapeutics Presents New Marrow-Infiltrating Lymphocytes (MILs®) Data Demonstrating Broad Therapeutic Promise for Solid Tumor Cancers

PHILADELPHIA and BALTIMORE, Nov. 09, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs®) products for cancer immunotherapy, today presented new data demonstrating the therapeutic promise for MILs as a potential cancer immunother…

WindMIL Therapeutics Announces Marrow-Infiltrating Lymphocytes (MILs®) Data Selected for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

PHILADELPHIA and BALTIMORE, Oct. 20, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs®) products for cancer immunotherapy, today announced that data regarding MILs® as a potential cancer immunotherapy for hematological and soli…

WindMIL Therapeutics to Present at 2020 Virtual Cell & Gene Meeting on the Mesa

PHILADELPHIA and BALTIMORE, Oct. 05, 2020 (GLOBE NEWSWIRE) -- WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocyte (MILs®) products for cancer immunotherapy, today announced that Chairman and Chief Executive Officer Don Hayden will present at the annual Cell &am…

WindMIL Therapeutics Frequently Asked Questions

  • When was WindMIL Therapeutics founded?

    WindMIL Therapeutics was founded in 2016.

  • How many employees does WindMIL Therapeutics have?

    WindMIL Therapeutics has 25 employees.

  • Who are WindMIL Therapeutics competitors?

    Competitors of WindMIL Therapeutics include Gliknik, Aurora Biopharma and PIN Pharma.

  • Where is WindMIL Therapeutics headquarters?

    WindMIL Therapeutics headquarters is located at 1812 Ashland Ave #100, Baltimore.

  • Where are WindMIL Therapeutics offices?

    WindMIL Therapeutics has offices in Baltimore and Philadelphia.

  • How many offices does WindMIL Therapeutics have?

    WindMIL Therapeutics has 2 offices.